{"id":344700,"date":"2025-08-24T13:49:09","date_gmt":"2025-08-24T13:49:09","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-catalyst-pharmaceuticals\/"},"modified":"2025-08-24T13:49:09","modified_gmt":"2025-08-24T13:49:09","slug":"how-to-buy-catalyst-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","title":{"rendered":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344700","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Catalyst Pharmaceuticals, Inc. (CPRX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131, g\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini kapsayan kapsaml\u0131 yat\u0131r\u0131m rehberimizle \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Catalyst Pharmaceuticals, Inc. (CPRX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131, g\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini kapsayan kapsaml\u0131 yat\u0131r\u0131m rehberimizle \u00f6\u011frenin."},"intro":"Nadir hastal\u0131k tedavilerinde \u00e7\u0131\u011f\u0131r a\u00e7an bir ila\u00e7 \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Catalyst Pharmaceuticals (CPRX), ileri bilim ile etkileyici finansal performans\u0131 birle\u015ftiriyor\u2014sa\u011fl\u0131k sekt\u00f6r\u00fcnde b\u00fcy\u00fcme arayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. D\u00fcnyada binlerce ki\u015fiyi etkileyen hastal\u0131klar i\u00e7in tedaviler sunan bu \u015firket, hem t\u0131bbi yenilik hem de yat\u0131r\u0131m f\u0131rsat\u0131 temsil ediyor.","intro_source":{"label":"Intro","type":"text","formatted_value":"Nadir hastal\u0131k tedavilerinde \u00e7\u0131\u011f\u0131r a\u00e7an bir ila\u00e7 \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Catalyst Pharmaceuticals (CPRX), ileri bilim ile etkileyici finansal performans\u0131 birle\u015ftiriyor\u2014sa\u011fl\u0131k sekt\u00f6r\u00fcnde b\u00fcy\u00fcme arayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. D\u00fcnyada binlerce ki\u015fiyi etkileyen hastal\u0131klar i\u00e7in tedaviler sunan bu \u015firket, hem t\u0131bbi yenilik hem de yat\u0131r\u0131m f\u0131rsat\u0131 temsil ediyor."},"body_html":"<h2>\ud83d\udcc8 Catalyst Pharmaceuticals Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>24 A\u011fustos 2025 itibar\u0131yla, Catalyst Pharmaceuticals, Inc. (CPRX) NASDAQ'ta <strong>20,23 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin g\u00fc\u00e7l\u00fc 2025 2. \u00e7eyrek kazan\u00e7 performans\u0131n\u0131 ve devam eden b\u00fcy\u00fcme e\u011filimini yans\u0131t\u0131yor.<\/p> <p><strong>Takviminize not edin: 5 Kas\u0131m 2025 kesinlikle kritik.<\/strong> Catalyst'in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar hisse senedinde \u00f6nemli hareketlere neden olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 CPRX Hissesini Nas\u0131l Hareket Ettirir<\/h3> <p>Son tarihleri inceledi\u011fimizde kazan\u00e7 kaynakl\u0131 volatilitenin net bir \u00f6r\u00fcnt\u00fcs\u00fc g\u00f6r\u00fcl\u00fcyor:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>6 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7<\/td><td>19,68 $<\/td><td><strong>%2,8 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td><\/tr> <tr><td>7 May 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7<\/td><td>21,50 $<\/td><td><strong>%4,2 D\u00fc\u015f\u00fc\u015f<\/strong> (kar\u0131\u015f\u0131k sonu\u00e7lar)<\/td><\/tr> <tr><td>26 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td><td>22,10 $<\/td><td><strong>%3,1 Art\u0131\u015f<\/strong> (g\u00fc\u00e7l\u00fc rehberlik)<\/td><\/tr> <tr><td>6 Kas 2024<\/td><td>3. \u00c7eyrek Kazan\u00e7<\/td><td>20,80 $<\/td><td><strong>%5,8 Art\u0131\u015f<\/strong> (gelir s\u00fcrprizi)<\/td><\/tr> <tr><td>7 A\u011fu 2024<\/td><td>2. \u00c7eyrek Kazan\u00e7<\/td><td>19,20 $<\/td><td><strong>%9,4 Art\u0131\u015f<\/strong> (rekor \u00e7eyrek)<\/td><\/tr> <tr><td>9 May 2024<\/td><td>\u00dcr\u00fcn Lansman\u0131<\/td><td>18,50 $<\/td><td><strong>%7,0 Art\u0131\u015f<\/strong> (pazar geni\u015flemesi)<\/td><\/tr> <\/tbody> <\/table> <p><strong>E\u011filim Analizi:<\/strong> Pozitif kazan\u00e7 s\u00fcrprizleri genellikle CPRX'i %5-9 oran\u0131nda y\u00fckseltirken, beklentilerin alt\u0131nda kalan sonu\u00e7lar %3-5 d\u00fc\u015f\u00fc\u015fe neden olur. A\u011fustos 2024'teki %9,4'l\u00fck s\u0131\u00e7rama, iyi haberlerin bu biyotek hisse senedini ne kadar dramatik hareket ettirebilece\u011fini g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h2> <p>CPRX hisseleri bu d\u00f6nemde \u00f6nemli hareketler ya\u015fad\u0131, \u015fu anda <strong>y\u0131lba\u015f\u0131ndan bu yana m\u00fctevaz\u0131 bir art\u0131\u015f<\/strong> g\u00f6steriyor, volatiliteye ra\u011fmen:<\/p> <p><strong>Mart 2025:<\/strong> 22,50 $ (kazan\u00e7 sonras\u0131 iyimserlik)<br\/> <strong>Nisan 2025:<\/strong> 21,80 $ (sekt\u00f6r genelinde biyotek \u00e7ekilmesi)<br\/> <strong>May\u0131s 2025:<\/strong> 20,10 $ (1. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131)<br\/> <strong>Haziran 2025:<\/strong> 26,31 $ (<strong>t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi<\/strong> 10 Haziran'da ula\u015f\u0131ld\u0131)<br\/> <strong>Temmuz 2025:<\/strong> 23,40 $ (y\u00fckseklerden kar realizasyonu)<br\/> <strong>A\u011fustos 2025:<\/strong> 20,23 $ (mevcut konsolidasyon)<\/p> <p>Hisse senedi <strong>10 Haziran 2025'te 26,31 $ zirvesine ula\u015ft\u0131<\/strong> <a href=\"https:\/\/stockscan.io\/stocks\/CPRX\/forecast\">(StockScan)<\/a>, \u00f6nceki d\u00fc\u015f\u00fcklerden dramatik bir y\u00fckseli\u015fi temsil ediyor. Ancak o zamandan beri yakla\u015f\u0131k <strong>%23 oran\u0131nda geri \u00e7ekildi<\/strong>, bu da baz\u0131 analistler taraf\u0131ndan al\u0131m f\u0131rsat\u0131 olarak g\u00f6r\u00fcl\u00fcyor.<\/p> <h3>Volatilitenin Sebebi Nedir?<\/h3> <ul> <li><strong>Nadir hastal\u0131k ila\u00e7 onaylar\u0131n\u0131 etkileyen FDA d\u00fczenleyici geli\u015fmeleri<\/strong><\/li> <li><strong>\u00c7eyreklik kazan\u00e7 s\u00fcrprizleri<\/strong> - \u015firket son 4 \u00e7eyre\u011fin 3'\u00fcnde tahminleri a\u015ft\u0131<\/li> <li><strong>Daha geni\u015f biyotek sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131<\/strong> - faiz oranlar\u0131 ve d\u00fczenleyici haberlerden y\u00fcksek derecede etkilenir<\/li> <li><strong>\u00dcr\u00fcn hatt\u0131 klinik deneme g\u00fcncellemeleri<\/strong><\/li> <\/ul> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve \u015firket temellerine dayanarak:<\/p> <p><strong>2025 Y\u0131l Sonu:<\/strong> 25-28 $ (<strong>AL<\/strong>)<br\/> G\u00fc\u00e7l\u00fc 2. \u00e7eyrek sonu\u00e7lar\u0131 <a href=\"https:\/\/www.nasdaq.com\/articles\/catalyst-pharmaceuticals-q2-earnings-beat-firdapse-revenues-rise-y-y\">(Nasdaq)<\/a> %19,4 gelir art\u0131\u015f\u0131 ile y\u0131l sonuna kadar de\u011fer art\u0131\u015f\u0131n\u0131 destekliyor.<\/p> <p><strong>2026 Tahmini:<\/strong> 29-34 $<br\/> Analistler <a href=\"https:\/\/aipickup.com\/stock-prediction\/cprx-stock-forecast\">%37,52 b\u00fcy\u00fcme potansiyeli<\/a> \u00f6ng\u00f6r\u00fcyor, Agamree sat\u0131\u015flar\u0131 h\u0131zlan\u0131yor.<\/p> <p><strong>2028 Projeksiyonu:<\/strong> 36-40 $<br\/> \u00dcr\u00fcn hatt\u0131 geni\u015flemesi ve uluslararas\u0131 pazar penetrasyonu \u00f6nemli de\u011fer yaratabilir.<\/p> <p><strong>2030 G\u00f6r\u00fcn\u00fcm\u00fc:<\/strong> 22-25 $<br\/> Uzun vadeli projeksiyonlar, patent korumalar\u0131n\u0131n sona ermesiyle bir miktar konsolidasyon g\u00f6steriyor.<\/p> <p><strong>Sonu\u00e7: 2025-2026 i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/strong> - Haziran zirvelerinden sonraki mevcut geri \u00e7ekilme, b\u00fcy\u00fcme odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in cazip giri\u015f noktas\u0131d\u0131r.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>FDA D\u00fczenleyici Riski:<\/strong> En b\u00fcy\u00fck tehdit - olumsuz bir d\u00fczenleyici karar \"hisseyi bir gecede \u00e7\u00f6kertir\" <a href=\"https:\/\/www.youtube.com\/watch?v=X_tInhuBbI8\">(Yat\u0131r\u0131m Analizi)<\/a>. Biyotek sekt\u00f6r\u00fc 2025'te \"artm\u0131\u015f g\u00fcvenlik incelemesi\" ile kar\u015f\u0131 kar\u015f\u0131ya.<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 Konsantrasyonu:<\/strong> Gelirin %94'\u00fc Firdapse'a ba\u011fl\u0131, rekabet veya fiyat bask\u0131s\u0131 artarsa k\u0131r\u0131lganl\u0131k yarat\u0131r.<\/li> <li><strong>Piyasa Volatilitesi:<\/strong> 0,78 beta de\u011feri, baz\u0131 biyotek hisselerine g\u00f6re daha az dramatik hareketler anlam\u0131na gelir, ancak sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131na tabidir.<\/li> <li><strong>Patent S\u00fcresi Dolmalar\u0131:<\/strong> On y\u0131l\u0131n sonlar\u0131na do\u011fru \u00f6nemli ila\u00e7 korumalar\u0131n\u0131n sona ermesi uzun vadeli risktir.<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Rekor Finansal Performans:<\/strong> 2025 2. \u00e7eyrek <a href=\"https:\/\/www.stocktitan.net\/news\/CPRX\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-2chcg39j187j.html\">146,6 milyon $ gelir (+%19,4 Y\/Y)<\/a> ve tahminlerin \u00fczerinde 0,68 $ EPS.<\/li> <li><strong>Rehberlik Kapsam\u0131:<\/strong> LEMS antikor testi, K\u00fc\u00e7\u00fck H\u00fccreli Akci\u011fer Kanseri i\u00e7in NCCN Klinik Uygulama Rehberlerine eklendi - re\u00e7ete art\u0131\u015f\u0131n\u0131 tetikleyebilecek \u00f6nemli bir onay.<\/li> <li><strong>G\u00fc\u00e7l\u00fc Bilan\u00e7o:<\/strong> 652,8 milyon $ nakit ve bor\u00e7suz, sat\u0131n almalar veya Ar-Ge yat\u0131r\u0131mlar\u0131 i\u00e7in finansal esneklik sa\u011fl\u0131yor.<\/li> <li><strong>Analist Deste\u011fi:<\/strong> Ortalama fiyat hedefi 34,00 $ olup, Wall Street analistlerine g\u00f6re <a href=\"https:\/\/www.zacks.com\/stock\/research\/CPRX\/price-target-stock-forecast\">%62 y\u00fckseli\u015f potansiyeli<\/a> sunuyor.<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>Ortalama Maliyetle Yat\u0131r\u0131m Yap\u0131n:<\/strong> Volatilite nedeniyle, m\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine haftal\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Kurun:<\/strong> 5 Kas\u0131m'\u0131 i\u015faretleyin ve kazan\u00e7 sonras\u0131 olas\u0131 hareketlere haz\u0131rlan\u0131n<\/li> <li><strong>Risk Y\u00f6netimi:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'dan fazlas\u0131n\u0131 tek bir biyotek hissesine ay\u0131rmay\u0131n<\/li> <li><strong>Uzun Vadeli Bak\u0131\u015f A\u00e7\u0131s\u0131:<\/strong> Biyotek yat\u0131r\u0131m\u0131, d\u00fczenleyici d\u00f6ng\u00fcler boyunca sab\u0131r gerektirir<\/li> <\/ol> <p>Mizahi bir yorum: \"CPRX ticareti yapmak, t\u0131bbi drama izlemek gibidir - bolca gerilim, ara s\u0131ra at\u0131l\u0131mlar ve FDA'n\u0131n ne zaman k\u00f6t\u00fc adam rol\u00fc oynayaca\u011f\u0131n\u0131 asla bilemezsiniz!\"<\/p> <h2>\u2705 Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul komisyon \u00fccretleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Volatil biyotekte risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"CPRX\" aramas\u0131 yap\u0131n<\/td><td>\u015eirket ad\u0131 yerine borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri, volatil d\u00f6nemlerde fazla \u00f6deme yapmay\u0131 \u00f6nler<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Sat\u0131n alma i\u015flemini tamamlamadan \u00f6nce emir detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, CPRX gibi hisselerde i\u015flem yapmak i\u00e7in \u00e7e\u015fitli avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - basit belge y\u00fckleme ile h\u0131zl\u0131ca i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> - karlar\u0131n\u0131za eri\u015fimde esneklik<\/li> <li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> - biyotek yat\u0131r\u0131m\u0131n\u0131 \u00f6\u011frenmek i\u00e7in sezgisel aray\u00fcz<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Catalyst Pharmaceuticals: Nadir Hastal\u0131k Uzman\u0131<\/h2> <p>Catalyst Pharmaceuticals, Lambert-Eaton Myastenik Sendromu (LEMS) tedavisinde \u00f6nde gelen \u00fcr\u00fcn\u00fc Firdapse ile nadir n\u00f6rolojik hastal\u0131k pazar\u0131nda hakimiyet kuruyor. \u015eirket, ba\u011f\u0131ml\u0131l\u0131k tedavilerinden ba\u015flayarak <a href=\"https:\/\/catalystpharma.com\/about-catalyst\/\">odaklanm\u0131\u015f nadir hastal\u0131k uzman\u0131<\/a> haline gelmi\u015f ve misyon odakl\u0131 bir yakla\u015f\u0131m benimsemi\u015ftir.<\/p> <p>\u015eirketin dikkat \u00e7ekici finansal d\u00f6n\u00fc\u015f\u00fcm\u00fc, <a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/cprx-history-mission-ownership\">Forbes'un 2025 Amerika'n\u0131n En Ba\u015far\u0131l\u0131 Orta \u00d6l\u00e7ekli \u015eirketleri listesinde be\u015finci s\u0131rada yer almas\u0131yla<\/a> ve y\u0131ll\u0131k yakla\u015f\u0131k 500 milyon $ gelirle kan\u0131tlanmaktad\u0131r.<\/p> <p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek:<\/strong> Catalyst'in hasta destek programlar\u0131 art\u0131k yapay zeka destekli tedavi uyum takibi i\u00e7eriyor - makine \u00f6\u011frenimi kullanarak re\u00e7ete yenileme kal\u0131plar\u0131 ve klinik sonu\u00e7 verilerine dayanarak hangi hastalar\u0131n ek deste\u011fe ihtiya\u00e7 duyabilece\u011fini tahmin ediyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Catalyst Pharmaceuticals Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>24 A\u011fustos 2025 itibar\u0131yla, Catalyst Pharmaceuticals, Inc. (CPRX) NASDAQ&#8217;ta <strong>20,23 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Bu fiyat, \u015firketin g\u00fc\u00e7l\u00fc 2025 2. \u00e7eyrek kazan\u00e7 performans\u0131n\u0131 ve devam eden b\u00fcy\u00fcme e\u011filimini yans\u0131t\u0131yor.<\/p>\n<p><strong>Takviminize not edin: 5 Kas\u0131m 2025 kesinlikle kritik.<\/strong> Catalyst&#8217;in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar hisse senedinde \u00f6nemli hareketlere neden olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 CPRX Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<p>Son tarihleri inceledi\u011fimizde kazan\u00e7 kaynakl\u0131 volatilitenin net bir \u00f6r\u00fcnt\u00fcs\u00fc g\u00f6r\u00fcl\u00fcyor:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7<\/td>\n<td>19,68 $<\/td>\n<td><strong>%2,8 Art\u0131\u015f<\/strong> (tahminleri a\u015ft\u0131)<\/td>\n<\/tr>\n<tr>\n<td>7 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7<\/td>\n<td>21,50 $<\/td>\n<td><strong>%4,2 D\u00fc\u015f\u00fc\u015f<\/strong> (kar\u0131\u015f\u0131k sonu\u00e7lar)<\/td>\n<\/tr>\n<tr>\n<td>26 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Sonu\u00e7lar<\/td>\n<td>22,10 $<\/td>\n<td><strong>%3,1 Art\u0131\u015f<\/strong> (g\u00fc\u00e7l\u00fc rehberlik)<\/td>\n<\/tr>\n<tr>\n<td>6 Kas 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7<\/td>\n<td>20,80 $<\/td>\n<td><strong>%5,8 Art\u0131\u015f<\/strong> (gelir s\u00fcrprizi)<\/td>\n<\/tr>\n<tr>\n<td>7 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7<\/td>\n<td>19,20 $<\/td>\n<td><strong>%9,4 Art\u0131\u015f<\/strong> (rekor \u00e7eyrek)<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>\u00dcr\u00fcn Lansman\u0131<\/td>\n<td>18,50 $<\/td>\n<td><strong>%7,0 Art\u0131\u015f<\/strong> (pazar geni\u015flemesi)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>E\u011filim Analizi:<\/strong> Pozitif kazan\u00e7 s\u00fcrprizleri genellikle CPRX&#8217;i %5-9 oran\u0131nda y\u00fckseltirken, beklentilerin alt\u0131nda kalan sonu\u00e7lar %3-5 d\u00fc\u015f\u00fc\u015fe neden olur. A\u011fustos 2024&#8217;teki %9,4&#8217;l\u00fck s\u0131\u00e7rama, iyi haberlerin bu biyotek hisse senedini ne kadar dramatik hareket ettirebilece\u011fini g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Seyri (Mart-A\u011fustos 2025)<\/h2>\n<p>CPRX hisseleri bu d\u00f6nemde \u00f6nemli hareketler ya\u015fad\u0131, \u015fu anda <strong>y\u0131lba\u015f\u0131ndan bu yana m\u00fctevaz\u0131 bir art\u0131\u015f<\/strong> g\u00f6steriyor, volatiliteye ra\u011fmen:<\/p>\n<p><strong>Mart 2025:<\/strong> 22,50 $ (kazan\u00e7 sonras\u0131 iyimserlik)<br \/> <strong>Nisan 2025:<\/strong> 21,80 $ (sekt\u00f6r genelinde biyotek \u00e7ekilmesi)<br \/> <strong>May\u0131s 2025:<\/strong> 20,10 $ (1. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131)<br \/> <strong>Haziran 2025:<\/strong> 26,31 $ (<strong>t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi<\/strong> 10 Haziran&#8217;da ula\u015f\u0131ld\u0131)<br \/> <strong>Temmuz 2025:<\/strong> 23,40 $ (y\u00fckseklerden kar realizasyonu)<br \/> <strong>A\u011fustos 2025:<\/strong> 20,23 $ (mevcut konsolidasyon)<\/p>\n<p>Hisse senedi <strong>10 Haziran 2025&#8217;te 26,31 $ zirvesine ula\u015ft\u0131<\/strong> <a href=\"https:\/\/stockscan.io\/stocks\/CPRX\/forecast\">(StockScan)<\/a>, \u00f6nceki d\u00fc\u015f\u00fcklerden dramatik bir y\u00fckseli\u015fi temsil ediyor. Ancak o zamandan beri yakla\u015f\u0131k <strong>%23 oran\u0131nda geri \u00e7ekildi<\/strong>, bu da baz\u0131 analistler taraf\u0131ndan al\u0131m f\u0131rsat\u0131 olarak g\u00f6r\u00fcl\u00fcyor.<\/p>\n<h3>Volatilitenin Sebebi Nedir?<\/h3>\n<ul>\n<li><strong>Nadir hastal\u0131k ila\u00e7 onaylar\u0131n\u0131 etkileyen FDA d\u00fczenleyici geli\u015fmeleri<\/strong><\/li>\n<li><strong>\u00c7eyreklik kazan\u00e7 s\u00fcrprizleri<\/strong> &#8211; \u015firket son 4 \u00e7eyre\u011fin 3&#8217;\u00fcnde tahminleri a\u015ft\u0131<\/li>\n<li><strong>Daha geni\u015f biyotek sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131<\/strong> &#8211; faiz oranlar\u0131 ve d\u00fczenleyici haberlerden y\u00fcksek derecede etkilenir<\/li>\n<li><strong>\u00dcr\u00fcn hatt\u0131 klinik deneme g\u00fcncellemeleri<\/strong><\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve \u015firket temellerine dayanarak:<\/p>\n<p><strong>2025 Y\u0131l Sonu:<\/strong> 25-28 $ (<strong>AL<\/strong>)<br \/> G\u00fc\u00e7l\u00fc 2. \u00e7eyrek sonu\u00e7lar\u0131 <a href=\"https:\/\/www.nasdaq.com\/articles\/catalyst-pharmaceuticals-q2-earnings-beat-firdapse-revenues-rise-y-y\">(Nasdaq)<\/a> %19,4 gelir art\u0131\u015f\u0131 ile y\u0131l sonuna kadar de\u011fer art\u0131\u015f\u0131n\u0131 destekliyor.<\/p>\n<p><strong>2026 Tahmini:<\/strong> 29-34 $<br \/> Analistler <a href=\"https:\/\/aipickup.com\/stock-prediction\/cprx-stock-forecast\">%37,52 b\u00fcy\u00fcme potansiyeli<\/a> \u00f6ng\u00f6r\u00fcyor, Agamree sat\u0131\u015flar\u0131 h\u0131zlan\u0131yor.<\/p>\n<p><strong>2028 Projeksiyonu:<\/strong> 36-40 $<br \/> \u00dcr\u00fcn hatt\u0131 geni\u015flemesi ve uluslararas\u0131 pazar penetrasyonu \u00f6nemli de\u011fer yaratabilir.<\/p>\n<p><strong>2030 G\u00f6r\u00fcn\u00fcm\u00fc:<\/strong> 22-25 $<br \/> Uzun vadeli projeksiyonlar, patent korumalar\u0131n\u0131n sona ermesiyle bir miktar konsolidasyon g\u00f6steriyor.<\/p>\n<p><strong>Sonu\u00e7: 2025-2026 i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/strong> &#8211; Haziran zirvelerinden sonraki mevcut geri \u00e7ekilme, b\u00fcy\u00fcme odakl\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in cazip giri\u015f noktas\u0131d\u0131r.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>FDA D\u00fczenleyici Riski:<\/strong> En b\u00fcy\u00fck tehdit &#8211; olumsuz bir d\u00fczenleyici karar &#8220;hisseyi bir gecede \u00e7\u00f6kertir&#8221; <a href=\"https:\/\/www.youtube.com\/watch?v=X_tInhuBbI8\">(Yat\u0131r\u0131m Analizi)<\/a>. Biyotek sekt\u00f6r\u00fc 2025&#8217;te &#8220;artm\u0131\u015f g\u00fcvenlik incelemesi&#8221; ile kar\u015f\u0131 kar\u015f\u0131ya.<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 Konsantrasyonu:<\/strong> Gelirin %94&#8217;\u00fc Firdapse&#8217;a ba\u011fl\u0131, rekabet veya fiyat bask\u0131s\u0131 artarsa k\u0131r\u0131lganl\u0131k yarat\u0131r.<\/li>\n<li><strong>Piyasa Volatilitesi:<\/strong> 0,78 beta de\u011feri, baz\u0131 biyotek hisselerine g\u00f6re daha az dramatik hareketler anlam\u0131na gelir, ancak sekt\u00f6r duyarl\u0131l\u0131\u011f\u0131na tabidir.<\/li>\n<li><strong>Patent S\u00fcresi Dolmalar\u0131:<\/strong> On y\u0131l\u0131n sonlar\u0131na do\u011fru \u00f6nemli ila\u00e7 korumalar\u0131n\u0131n sona ermesi uzun vadeli risktir.<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Rekor Finansal Performans:<\/strong> 2025 2. \u00e7eyrek <a href=\"https:\/\/www.stocktitan.net\/news\/CPRX\/catalyst-pharmaceuticals-reports-record-second-quarter-and-first-2chcg39j187j.html\">146,6 milyon $ gelir (+%19,4 Y\/Y)<\/a> ve tahminlerin \u00fczerinde 0,68 $ EPS.<\/li>\n<li><strong>Rehberlik Kapsam\u0131:<\/strong> LEMS antikor testi, K\u00fc\u00e7\u00fck H\u00fccreli Akci\u011fer Kanseri i\u00e7in NCCN Klinik Uygulama Rehberlerine eklendi &#8211; re\u00e7ete art\u0131\u015f\u0131n\u0131 tetikleyebilecek \u00f6nemli bir onay.<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Bilan\u00e7o:<\/strong> 652,8 milyon $ nakit ve bor\u00e7suz, sat\u0131n almalar veya Ar-Ge yat\u0131r\u0131mlar\u0131 i\u00e7in finansal esneklik sa\u011fl\u0131yor.<\/li>\n<li><strong>Analist Deste\u011fi:<\/strong> Ortalama fiyat hedefi 34,00 $ olup, Wall Street analistlerine g\u00f6re <a href=\"https:\/\/www.zacks.com\/stock\/research\/CPRX\/price-target-stock-forecast\">%62 y\u00fckseli\u015f potansiyeli<\/a> sunuyor.<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>Ortalama Maliyetle Yat\u0131r\u0131m Yap\u0131n:<\/strong> Volatilite nedeniyle, m\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine haftal\u0131k sabit tutarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Kurun:<\/strong> 5 Kas\u0131m&#8217;\u0131 i\u015faretleyin ve kazan\u00e7 sonras\u0131 olas\u0131 hareketlere haz\u0131rlan\u0131n<\/li>\n<li><strong>Risk Y\u00f6netimi:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;dan fazlas\u0131n\u0131 tek bir biyotek hissesine ay\u0131rmay\u0131n<\/li>\n<li><strong>Uzun Vadeli Bak\u0131\u015f A\u00e7\u0131s\u0131:<\/strong> Biyotek yat\u0131r\u0131m\u0131, d\u00fczenleyici d\u00f6ng\u00fcler boyunca sab\u0131r gerektirir<\/li>\n<\/ol>\n<p>Mizahi bir yorum: &#8220;CPRX ticareti yapmak, t\u0131bbi drama izlemek gibidir &#8211; bolca gerilim, ara s\u0131ra at\u0131l\u0131mlar ve FDA&#8217;n\u0131n ne zaman k\u00f6t\u00fc adam rol\u00fc oynayaca\u011f\u0131n\u0131 asla bilemezsiniz!&#8221;<\/p>\n<h2>\u2705 Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul komisyon \u00fccretleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Volatil biyotekte risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;CPRX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>\u015eirket ad\u0131 yerine borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri, volatil d\u00f6nemlerde fazla \u00f6deme yapmay\u0131 \u00f6nler<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Sat\u0131n alma i\u015flemini tamamlamadan \u00f6nce emir detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, CPRX gibi hisselerde i\u015flem yapmak i\u00e7in \u00e7e\u015fitli avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; stratejileri d\u00fc\u015f\u00fck riskle test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; basit belge y\u00fckleme ile h\u0131zl\u0131ca i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; karlar\u0131n\u0131za eri\u015fimde esneklik<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> &#8211; biyotek yat\u0131r\u0131m\u0131n\u0131 \u00f6\u011frenmek i\u00e7in sezgisel aray\u00fcz<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Catalyst Pharmaceuticals: Nadir Hastal\u0131k Uzman\u0131<\/h2>\n<p>Catalyst Pharmaceuticals, Lambert-Eaton Myastenik Sendromu (LEMS) tedavisinde \u00f6nde gelen \u00fcr\u00fcn\u00fc Firdapse ile nadir n\u00f6rolojik hastal\u0131k pazar\u0131nda hakimiyet kuruyor. \u015eirket, ba\u011f\u0131ml\u0131l\u0131k tedavilerinden ba\u015flayarak <a href=\"https:\/\/catalystpharma.com\/about-catalyst\/\">odaklanm\u0131\u015f nadir hastal\u0131k uzman\u0131<\/a> haline gelmi\u015f ve misyon odakl\u0131 bir yakla\u015f\u0131m benimsemi\u015ftir.<\/p>\n<p>\u015eirketin dikkat \u00e7ekici finansal d\u00f6n\u00fc\u015f\u00fcm\u00fc, <a href=\"https:\/\/dcfmodeling.com\/blogs\/history\/cprx-history-mission-ownership\">Forbes&#8217;un 2025 Amerika&#8217;n\u0131n En Ba\u015far\u0131l\u0131 Orta \u00d6l\u00e7ekli \u015eirketleri listesinde be\u015finci s\u0131rada yer almas\u0131yla<\/a> ve y\u0131ll\u0131k yakla\u015f\u0131k 500 milyon $ gelirle kan\u0131tlanmaktad\u0131r.<\/p>\n<p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek:<\/strong> Catalyst&#8217;in hasta destek programlar\u0131 art\u0131k yapay zeka destekli tedavi uyum takibi i\u00e7eriyor &#8211; makine \u00f6\u011frenimi kullanarak re\u00e7ete yenileme kal\u0131plar\u0131 ve klinik sonu\u00e7 verilerine dayanarak hangi hastalar\u0131n ek deste\u011fe ihtiya\u00e7 duyabilece\u011fini tahmin ediyor.<\/p>\n"},"faq":[{"question":"Catalyst Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, CPRX sembol\u00fc ile arama yap\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in ve sat\u0131n alma i\u015flemini onaylay\u0131n."},{"question":"Catalyst Pharmaceuticals'\u0131n ana \u00fcr\u00fcn\u00fc nedir?","answer":"\u015eirketin ana \u00fcr\u00fcn\u00fc Lambert-Eaton Myastenik Sendromu (LEMS) tedavisinde kullan\u0131lan Firdapse'tir."},{"question":"Catalyst Pharmaceuticals hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 25-28 $ aras\u0131, 2026'da 29-34 $, 2028'de 36-40 $ ve 2030'da 22-25 $ aras\u0131 fiyatlar \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Catalyst Pharmaceuticals yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"FDA d\u00fczenleyici riskleri, \u00fcr\u00fcn hatt\u0131 konsantrasyonu, piyasa volatilitesi ve patent s\u00fcresi dolmalar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Catalyst Pharmaceuticals hisselerine nas\u0131l yakla\u015fmal\u0131?","answer":"D\u00fczenli yat\u0131r\u0131m yapmal\u0131, kazan\u00e7 uyar\u0131lar\u0131 kurmal\u0131, risk y\u00f6netimi uygulamal\u0131 ve uzun vadeli bak\u0131\u015f a\u00e7\u0131s\u0131 benimsemelidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Catalyst Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, CPRX sembol\u00fc ile arama yap\u0131n, emir t\u00fcr\u00fcn\u00fc se\u00e7in ve sat\u0131n alma i\u015flemini onaylay\u0131n."},{"question":"Catalyst Pharmaceuticals'\u0131n ana \u00fcr\u00fcn\u00fc nedir?","answer":"\u015eirketin ana \u00fcr\u00fcn\u00fc Lambert-Eaton Myastenik Sendromu (LEMS) tedavisinde kullan\u0131lan Firdapse'tir."},{"question":"Catalyst Pharmaceuticals hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 25-28 $ aras\u0131, 2026'da 29-34 $, 2028'de 36-40 $ ve 2030'da 22-25 $ aras\u0131 fiyatlar \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Catalyst Pharmaceuticals yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"FDA d\u00fczenleyici riskleri, \u00fcr\u00fcn hatt\u0131 konsantrasyonu, piyasa volatilitesi ve patent s\u00fcresi dolmalar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Catalyst Pharmaceuticals hisselerine nas\u0131l yakla\u015fmal\u0131?","answer":"D\u00fczenli yat\u0131r\u0131m yapmal\u0131, kazan\u00e7 uyar\u0131lar\u0131 kurmal\u0131, risk y\u00f6netimi uygulamal\u0131 ve uzun vadeli bak\u0131\u015f a\u00e7\u0131s\u0131 benimsemelidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T13:49:09+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-24T13:49:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\",\"name\":\"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-24T13:49:09+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T13:49:09+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-24T13:49:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/","name":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-24T13:49:09+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Catalyst Pharmaceuticals, Inc. (CPRX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Catalyst Pharmaceuticals, Inc. (CPRX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":344702,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":344699,"slug":"how-to-buy-catalyst-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Catalyst Pharmaceuticals, Inc. (CPRX) - Investimento em a\u00e7\u00f5es da Catalyst Pharmaceuticals, Inc. (CPRX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-catalyst-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=344700"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/344700\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=344700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=344700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=344700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}